



BACTERIAL AND VIRUS VESICLES WORKSHOP

ABSTRACT SUBMISSION GUIDELINES

Key Dates:

Abstract Launch	June 10, 2026
Abstract Close	July 10, 2026
Author Notifications	July 16, 2026
Presenting Author Registration Deadline	September 1, 2026

ISEV invites abstracts across these four tracks:

Track 1 – Bacterial Vesicles: Biogenesis, Cargo, and Heterogeneity

Track 2 – Virus-Induced Extracellular Vesicles: Biogenesis, Cargo, and Heterogeneity

Track 3 – Vesicle-Mediated Host-Microbe Communication, Vesicles in Viral Transmission, Immune Modulations

Track 4 – Diagnostic, Preventative, and Therapeutic Strategies Based on Bacterial and Viral Vesicles

Abstracts are welcome from across the ecosystem: Academic researchers, technology developers, biotech and pharma scientists, clinical investigators, regulatory and translational specialists, and trainees entering the EV field. This focused meeting aims to bring together experts working on bacterial vesicles and virus-associated EVs to exchange recent advances, discuss shared challenges, and identify future directions in the field.

Registration for this workshop is by invitation only and based on accepted abstracts. There is no registration fee.

Submission Guidelines

1. Please consult the [Minimal Information for Studies of EVs \(MISEV2023\)](#) and ensure that your abstract is responsive to the guidelines, including on nomenclature, sample processing, separation, characterization, functional studies, and reporting.
2. The title of the abstract should not exceed 210 characters, and the main body of the abstract should not exceed 2,000 characters.
3. The submission portal will include separate categories for Introduction, Methods, Results, and Summary/Conclusions. Please organize your abstract according to this structure.
4. Capitalize only the first letter of the first word of the title (unless for abbreviations or proper nouns) and do not end the title with a period ("."). Do not include quotation marks.
5. The abstract must contain primary scientific or clinical data that has not been published elsewhere and has not been presented previously at an ISEV meeting. Do not partition results

from the same study into multiple abstracts, and do not submit a copy or close copy of an abstract under more than one theme.

6. The abstract submitter is responsible for ensuring that all authors have read the abstract and agreed to be coauthors.
7. Clearly indicate molecular findings with consensus names, not generic identifiers like “Protein X” and “miRNA Y”. Abstracts without these details may be rejected. Please note if a patent is pending and therefore limiting information disclosure.
8. Submitted abstracts on human subjects must have ethical approval and state whether informed consent was obtained. Animal studies need to be approved by the relevant animal use committees.
9. If off-label/unlicensed use of drugs was involved in the study, please state this clearly.
10. The abstract title and text may not contain trade names. ISEV reserves the right to replace trade names in accepted abstracts.
11. Abstracts should be submitted in English.
12. Choose the preferred presentation mode: oral or poster.

Withdrawal Policy

To withdraw an accepted abstract from presentation or publication, send an e-mail to ISEV (contact@isev.org) before **September 1**. Withdrawn abstracts cannot be presented.